These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
238 related articles for article (PubMed ID: 32881954)
21. Effect of NMO-IgG on the interleukin-6 cascade in astrocytes via activation of the JAK/STAT3 signaling pathway. Du L; Chang H; Xu W; Wei Y; Wang Y; Yin L; Zhang X Life Sci; 2020 Oct; 258():118217. PubMed ID: 32768575 [TBL] [Abstract][Full Text] [Related]
22. Relationship between blood-brain permeability and antibodies against aquaporins in neuromyelitis optica spectrum disorders and multiple sclerosis patients. Jasiak-Zatońska M; Michalak S; Osztynowicz K; Kozubski W; Kalinowska-Łyszczarz A Neurol Neurochir Pol; 2022; 56(4):308-317. PubMed ID: 35029294 [TBL] [Abstract][Full Text] [Related]
23. NMO sera down-regulate AQP4 in human astrocyte and induce cytotoxicity independent of complement. Haruki H; Sano Y; Shimizu F; Omoto M; Tasaki A; Oishi M; Koga M; Saito K; Takahashi T; Nakada T; Kanda T J Neurol Sci; 2013 Aug; 331(1-2):136-44. PubMed ID: 23809190 [TBL] [Abstract][Full Text] [Related]
24. Complement-dependent bystander injury to neurons in AQP4-IgG seropositive neuromyelitis optica. Duan T; Smith AJ; Verkman AS J Neuroinflammation; 2018 Oct; 15(1):294. PubMed ID: 30348195 [TBL] [Abstract][Full Text] [Related]
25. Blood-brain barrier disruption is more severe in neuromyelitis optica than in multiple sclerosis and correlates with clinical disability. Tomizawa Y; Yokoyama K; Saiki S; Takahashi T; Matsuoka J; Hattori N J Int Med Res; 2012; 40(4):1483-91. PubMed ID: 22971500 [TBL] [Abstract][Full Text] [Related]
26. Targeting chemoattractant chemokine (C-C motif) ligand 2 derived from astrocytes is a promising therapeutic approach in the treatment of neuromyelitis optica spectrum disorders. Wang Y; Bian J; Yao M; Du L; Xu Y; Chang H; Cong H; Wei Y; Xu W; Wang H; Zhang X; Geng X; Yin L Front Immunol; 2023; 14():1144532. PubMed ID: 37056770 [TBL] [Abstract][Full Text] [Related]
27. Pathogenic potential of IgG binding to water channel extracellular domain in neuromyelitis optica. Hinson SR; Pittock SJ; Lucchinetti CF; Roemer SF; Fryer JP; Kryzer TJ; Lennon VA Neurology; 2007 Dec; 69(24):2221-31. PubMed ID: 17928579 [TBL] [Abstract][Full Text] [Related]
28. Anti-aquaporin-4 auto-antibodies orchestrate the pathogenesis in neuromyelitis optica. Saikali P; Cayrol R; Vincent T Autoimmun Rev; 2009 Dec; 9(2):132-5. PubMed ID: 19389490 [TBL] [Abstract][Full Text] [Related]
31. Increased cerebrospinal fluid metalloproteinase-2 and interleukin-6 are associated with albumin quotient in neuromyelitis optica: Their possible role on blood-brain barrier disruption. Uchida T; Mori M; Uzawa A; Masuda H; Muto M; Ohtani R; Kuwabara S Mult Scler; 2017 Jul; 23(8):1072-1084. PubMed ID: 27682231 [TBL] [Abstract][Full Text] [Related]
32. Distinct genetic and infectious profiles in Japanese neuromyelitis optica patients according to anti-aquaporin 4 antibody status. Yoshimura S; Isobe N; Matsushita T; Yonekawa T; Masaki K; Sato S; Kawano Y; Kira J; J Neurol Neurosurg Psychiatry; 2013 Jan; 84(1):29-34. PubMed ID: 23038741 [TBL] [Abstract][Full Text] [Related]
34. The Immunology of Neuromyelitis Optica-Current Knowledge, Clinical Implications, Controversies and Future Perspectives. Jasiak-Zatonska M; Kalinowska-Lyszczarz A; Michalak S; Kozubski W Int J Mol Sci; 2016 Mar; 17(3):273. PubMed ID: 26950113 [TBL] [Abstract][Full Text] [Related]
35. Resolution of inflammation in neuromyelitis optica spectrum disorders. Wang X; Jiao W; Lin M; Lu C; Liu C; Wang Y; Ma D; Wang X; Yin P; Feng J; Zhu J; Zhu M Mult Scler Relat Disord; 2019 Jan; 27():34-41. PubMed ID: 30300851 [TBL] [Abstract][Full Text] [Related]
36. Low Frequency Ultrasound With Injection of NMO-IgG and Complement Produces Lesions Different From Experimental Autoimmune Encephalomyelitis Mice. Xiang W; Xie C; Luo J; Zhang W; Zhao X; Yang H; Cai Y; Ding J; Wang Y; Hao Y; Zhang Y; Guan Y Front Immunol; 2021; 12():727750. PubMed ID: 34721390 [TBL] [Abstract][Full Text] [Related]
37. Astrocytic Interleukin-15 Reduces Pathology of Neuromyelitis Optica in Mice. Li Z; Han J; Ren H; Ma CG; Shi FD; Liu Q; Li M Front Immunol; 2018; 9():523. PubMed ID: 29616032 [TBL] [Abstract][Full Text] [Related]
38. Complement regulator CD59 prevents peripheral organ injury in rats made seropositive for neuromyelitis optica immunoglobulin G. Yao X; Verkman AS Acta Neuropathol Commun; 2017 Jul; 5(1):57. PubMed ID: 28750658 [TBL] [Abstract][Full Text] [Related]
39. Bystander mechanism for complement-initiated early oligodendrocyte injury in neuromyelitis optica. Tradtrantip L; Yao X; Su T; Smith AJ; Verkman AS Acta Neuropathol; 2017 Jul; 134(1):35-44. PubMed ID: 28567523 [TBL] [Abstract][Full Text] [Related]
40. CD55 upregulation in astrocytes by statins as potential therapy for AQP4-IgG seropositive neuromyelitis optica. Tradtrantip L; Duan T; Yeaman MR; Verkman AS J Neuroinflammation; 2019 Mar; 16(1):57. PubMed ID: 30851734 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]